我是 LongbridgeAI，我可以總結文章信息。Marksans Pharma 的股票在獲得美國 FDA 對止咳藥 Benzonatate 膠囊的批准後上漲了 7.9%。該股在盤中最高達到₹169.65。在 2026 財年第三季度，公司報告淨利潤為₹11,320.2 億，較去年同期的₹10,456.3 億有所增長，營業收入為₹754.42 億。董事總經理 Mark Saldanha 強調了公司的穩定表現和增長策略，包括在歐洲和加拿大的新子公司，旨在實現受監管市場的長期增長
Marksans Pharma shares spiked 7.9 per cent in trade on the BSE, logging an intra-day high at ₹169.65 per share. At 12:33 PM, Marksans Pharma’s share price was trading 7.67 per cent higher at ₹169.2 per share. In comparison, the BSE Sensex was up 2.46 per cent at 73,714.76.
The buying on the counter came after the company received US Food and Drug Administration (USFDA) approval to launch Benzonatate Capsules USP in 100 mg and 200 mg strengths in the US market.
In its filing, the company said that Benzonatate is the generic version of Pfizer’s Tessalon Capsules and is used to treat cough by reducing the cough reflex. It is prescribed for conditions such as bronchitis, pneumonia, and other lung infections.
That apart, in Q3FY26, the company reported net profit of ₹11,320.2 crore, as compared to ₹10,456.3 crore a year ago.
Its revenue from operations stood at ₹754.42 crore, as compared to ₹681.84 crore a year ago.
“We delivered a stable and resilient performance in Q3 FY26, with operating revenue growing 10.6 per cent year-on-year (Y-o-Y), supported by steady execution across key markets and improved seasonal demand. Margins expanded sequentially, driven by soft raw material costs, favorable currency movements, and an improving product mix, while Earnings before interest, tax, depreciation and amortisation (Ebitda) growth reflected operating leverage,” said Mark Saldanha, managing director, Marksans Pharma.
He added: During the quarter, we took measured steps to strengthen our global footprint through new subsidiaries in Europe and Canada, positioning the Company for long-term growth in regulated markets. We remain disciplined, execution focused, and committed to delivering sustainable growth and long-term shareholder value.
Marksans Pharma, headquartered in Mumbai, is engaged in research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities located in India, the USA, and the UK are approved by several leading regulatory agencies, including the USFDA, UKMHRA, and Australian TGA. The company's product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, upper respiratory, and gastroenterological. The company is marketing these products globally.